Fourth-quarter consumable sales were up 12 percent, with acquisitions contributing to 3.9 percent of that growth .
Net income for the period decreased 70 percent to $17.8 million from $59.8 million during the fourth quarter of 2004.
Beckman reaffirmed its outlook for 2006 that was stated on
For the first quarter of the year, sales should be $555 million to $575 million, Beckman said.
Beckman CEO Scott Garrett said he expects growth in 2006 to be led by placements of the company's DxC 600 and 800 Autochemistry platforms, and of the UniCel DxI 800 immunoassay systems.
Beckman did not break out its R&D spending for the fourth quarter or for the 2005 year.